{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:13:55Z","timestamp":1772086435588,"version":"3.50.1"},"reference-count":26,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>With the increasing prevalence of polypharmacy, age-related physiological changes, and the need for individualized pharmacotherapy in older patients, understanding new drug approvals is crucial to optimizing medication management. This review synthesizes the latest evidence on recently\n approved medications including Atzumi\u2122 and Brekiya\u00ae (dihydroergotamine mesylate) for migraine headaches, Attruby\u2122 (acoramidis) for transthyretin amyloid cardiomyopathy, and Blujepa\u00ae (gepotidacin) for uncomplicated urinary tract infections. Insights are offered into prescribing\n considerations for these agents in older populations, potential drug-drug interactions, and administration and handling tips. This work will be of significant interest to health care professionals as they evaluate the appropriateness of these new therapeutic options.<\/jats:p>","DOI":"10.4140\/tcp.n.2026.3","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:30:21Z","timestamp":1768969821000},"page":"3-12","source":"Crossref","is-referenced-by-count":0,"title":["2025 New Drug Update (Part 2): Recent Approvals and Clinical Implications"],"prefix":"10.4140","volume":"41","author":[{"given":"Sophie","family":"Friedman","sequence":"first","affiliation":[{"name":"1Northeastern University School of Pharmacy and Pharmaceutical Sciences, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Akerman","sequence":"additional","affiliation":[{"name":"2Harbor Health Elder Service Plan, Mattapan, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Bouwmeester","sequence":"additional","affiliation":[{"name":"1Northeastern University School of Pharmacy and Pharmaceutical Sciences, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4140\/TCP.n.2016.186.","article-title":"2016 New Drug Update.","volume":"31","year":"2016","journal-title":"Consult Pharm."},{"key":"ref2","year":"2025"},{"key":"ref3","year":"2025"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1526-4610.2003.03034.x","article-title":"Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.","volume":"43","year":"2003","journal-title":"Headache"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies.","volume":"55","year":"2015","journal-title":"Headache"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","article-title":"Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis.","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice.","volume":"61","year":"2021","journal-title":"Headache"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/head.13737","article-title":"A phase 1, randomized, open-label, safety, tolerability, and comparative bioavailability study of intranasal dihydroergotamine powder (STS101), intramuscular dihydroergotamine mesylate, and intranasal DHE mesylate spray in healthy adult subjects.","volume":"60","year":"2020","journal-title":"Headache"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-024-01118-8","article-title":"Long-term (12-month) safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine: data from the phase 3 open-label ASCEND study.","volume":"38","year":"2024","journal-title":"CNS Drugs"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1526-4610.2007.00803.x","article-title":"Patient information regarding subcutaneous self-administration of dihydroergotamine (DHE).","volume":"47","year":"2007","journal-title":"Headache"},{"key":"ref11","article-title":"Package insert. BridgeBio Pharma Inc;","year":"2024"},{"key":"ref12","article-title":"Transthyretin amyloid cardiomyopathy (ATTR-CM).","year":"2025","journal-title":"StatPearls. April 27, 2023 . Accessed August 13,"},{"issue":"suppl 4","key":"ref13","first-page":"16427","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity.","volume":"99","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"ref15","first-page":"e7","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association.","volume":"142","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis.","volume":"81","year":"2023","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"ref18","article-title":"Lexi-Drugs. UpToDate Lexidrug.","year":"2025","journal-title":"UpToDate Inc. Riverwoods, IL. Accessed June 6,"},{"key":"ref19","article-title":"Lexi-Drugs. UpToDate Lexidrug.","year":"2025","journal-title":"UpToDate Inc. Riverwoods, IL. Accessed June 6,"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.","volume":"11","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref21","article-title":"Package insert. GlaxoSmithKline;","year":"2025"},{"issue":"7309","key":"ref22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents.","volume":"466","year":"2010","journal-title":"Nature"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.","volume":"52","year":"2011","journal-title":"Clin Infect Dis."},{"key":"ref24","article-title":"Complicated urinary tract infections (cUTI): clinical guidelines for treatment and management. Infectious Diseases Society of America (IDSA). Published July 17, 2025.","journal-title":"Accessed October 17, 2025"},{"key":"ref25","first-page":"2018","article-title":"FDA drug safety communication: FDA updates warning for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Published May 12, 2016.","volume":"9","year":"2025","journal-title":"Updated March"},{"issue":"10428","key":"ref26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.","volume":"403","year":"2024","journal-title":"Lancet"}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2026\/00000041\/00000001\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:31:01Z","timestamp":1772080261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2026.3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["2639-9636(20260101)41:1L.3;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2026.3","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}